Objective： The aim of the present study is to explore the expression of a specific marker of breast cancer, small breast epithefial mucin （SBEM） mRNA, in peripheral blood and to investigate its significance. Method...Objective： The aim of the present study is to explore the expression of a specific marker of breast cancer, small breast epithefial mucin （SBEM） mRNA, in peripheral blood and to investigate its significance. Methods： The expressions of SBEM-mRNA in peripheral blood of 67 patients with breast cancer, 16 patients with benign breast disease, and 20 normal healthy volunteers were detected with nested reverse transcription-polymerase chain reaction （Nested-RT-PCR）. Results： SBEMomRNA was negative in healthy individuals and patients with benign breast tumor, but 50.7%（34/67） of breast cancer patients showed positive expression of SBEM-mRNA in peripheral blood, of whom 25%（2/8） were in stage Ⅰ, 45.8%（11/24） in stage Ⅱ, 43.75%（11/24） in stage Ⅲ and 73.7（14/19） in stage Ⅳ. The positive rate in stage Ⅳ was higher than that in stage Ⅰ, Ⅱ, Ⅲ （P〈0.05）. Expressions of SBEM-mRNA had no correlation with age, carcinoma size, pathological type, ER and PR state （P〉0.05）. Concision： SBEM-mRNA is specifically expressed in breast cancer and it may act as a marker for the detection of of breast cancer.展开更多
Objective: To study the clinical significance of human mammaglobin (hMAM) mRNA in peripheral blood of patients with breast cancer. Methods: The expression of hMAM mRNA was detected in peripheral blood from patients wi...Objective: To study the clinical significance of human mammaglobin (hMAM) mRNA in peripheral blood of patients with breast cancer. Methods: The expression of hMAM mRNA was detected in peripheral blood from patients with breast cancer, breast benign lesions, healthy volunteers by nested reverse transcription polymerase chain reaction (nested-RT-PCR) method. The possible correlations of hMAM mRNA expression with clinico-pathological parameters and related molecular markers such as p53, PCNA and HER-2 were analyzed. The hMAM mRNA changed in peripheral blood after chemotherapy was observed. Results: The positive rate of hMAM mRNA was 34.0% in peripheral blood of breast cancer, hMAM mRNA was not expressed in peripheral blood from other cancers, breast benign lesions or healthy volunteers. The expression of hMAM mRNA in peripheral blood was correlated with lymph nodes status and TNM stage. After 2-3 cycles adjuvant chemotherapy, In 13 of 17 cases, the positive hMAM mRNA turned to be negative, and there was statistical difference between pre-chemo- therapy and post-chemotherapy. Conclusion: hMAM mRNA has specific expression in breast cancer, the positive expression of hMAM mRNA in peripheral blood might predict hematogenous metastatic spreading of tumor cells, and hMAM mRNA may be potential biological marker for detecting breast cancer micrometastasis.展开更多
基金This work was supported by the Natural Science Foundation of Guangxi Province (No. 0640161).
文摘Objective： The aim of the present study is to explore the expression of a specific marker of breast cancer, small breast epithefial mucin （SBEM） mRNA, in peripheral blood and to investigate its significance. Methods： The expressions of SBEM-mRNA in peripheral blood of 67 patients with breast cancer, 16 patients with benign breast disease, and 20 normal healthy volunteers were detected with nested reverse transcription-polymerase chain reaction （Nested-RT-PCR）. Results： SBEMomRNA was negative in healthy individuals and patients with benign breast tumor, but 50.7%（34/67） of breast cancer patients showed positive expression of SBEM-mRNA in peripheral blood, of whom 25%（2/8） were in stage Ⅰ, 45.8%（11/24） in stage Ⅱ, 43.75%（11/24） in stage Ⅲ and 73.7（14/19） in stage Ⅳ. The positive rate in stage Ⅳ was higher than that in stage Ⅰ, Ⅱ, Ⅲ （P〈0.05）. Expressions of SBEM-mRNA had no correlation with age, carcinoma size, pathological type, ER and PR state （P〉0.05）. Concision： SBEM-mRNA is specifically expressed in breast cancer and it may act as a marker for the detection of of breast cancer.
文摘Objective: To study the clinical significance of human mammaglobin (hMAM) mRNA in peripheral blood of patients with breast cancer. Methods: The expression of hMAM mRNA was detected in peripheral blood from patients with breast cancer, breast benign lesions, healthy volunteers by nested reverse transcription polymerase chain reaction (nested-RT-PCR) method. The possible correlations of hMAM mRNA expression with clinico-pathological parameters and related molecular markers such as p53, PCNA and HER-2 were analyzed. The hMAM mRNA changed in peripheral blood after chemotherapy was observed. Results: The positive rate of hMAM mRNA was 34.0% in peripheral blood of breast cancer, hMAM mRNA was not expressed in peripheral blood from other cancers, breast benign lesions or healthy volunteers. The expression of hMAM mRNA in peripheral blood was correlated with lymph nodes status and TNM stage. After 2-3 cycles adjuvant chemotherapy, In 13 of 17 cases, the positive hMAM mRNA turned to be negative, and there was statistical difference between pre-chemo- therapy and post-chemotherapy. Conclusion: hMAM mRNA has specific expression in breast cancer, the positive expression of hMAM mRNA in peripheral blood might predict hematogenous metastatic spreading of tumor cells, and hMAM mRNA may be potential biological marker for detecting breast cancer micrometastasis.
